Meilleure Health International Industry Group Limited (2327) AI Stock Analysis

• Market Cap: HK$1.04B
• Dividend Yield: 1.6%
• Average Volume (3M): 870.67K
• Price to Earnings (P/E): 32.3
• Beta (1Y): 0.31
• Revenue Growth: -60.81%
• EPS Growth: -21.00%
• Country: HK
• Employees: 46
• Sector: Industrials
• Sector Strength: 84
• Industry: Conglomerates
• EPS (TTM): <0.01
• Shares Outstanding: 4,093,756,600
• 10 Day Avg. Volume: 595,400
• 30 Day Avg. Volume: 870,666
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$0.50
• Price Target Upside: 100.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: HK$0.50 ▲(100.00% Upside)

The overall stock score reflects significant financial volatility, negative technical indicators, and an expensive valuation. While the dividend yield provides some support, the lack of positive momentum and operational challenges weigh heavily on the stock.

Meilleure Health International Industry Group Limited Business Overview & Revenue Model

Company Description

Meilleure Health International Industry Group Limited (2327) is a diversified health and wellness company operating across various sectors, including healthcare, biotechnology, and health management services. The company primarily focuses on offering innovative health solutions and products, aiming to enhance the quality of life for individuals. Its core products and services encompass health supplements, medical devices, and related healthcare services designed to meet the growing demands of the global health industry.

How the Company Makes Money

Meilleure Health International Industry Group Limited generates revenue through multiple streams primarily centered around its health and wellness offerings. The company's revenue model includes the production and sale of health supplements and medical devices, which cater to a wide range of health needs. Additionally, it engages in providing health management services that support preventive care and wellness. Key partnerships with healthcare providers and distribution networks enhance its market reach and contribute significantly to its earnings. The company's focus on research and development also plays a crucial role in maintaining a competitive edge, allowing it to introduce new and improved products to the market.

Meilleure Health International Industry Group Limited Financial Statement Overview

Summary

Meilleure Health International Industry Group Limited displays a mixed financial performance with significant volatility across income, balance sheet, and cash flow metrics. The company has experienced fluctuations in revenue and inconsistent profitability, pointing to operational challenges and financial instability.

Income Statement

The company has experienced significant fluctuations in revenue, with a notable decline from 2020 to 2024. Gross profit margin and net profit margin have been inconsistent, indicating volatility in profitability. The EBIT and EBITDA margins have similarly varied, pointing to operational challenges.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a reasonable level of leverage. However, the equity ratio has been decreasing, which could suggest increasing liabilities relative to assets. Return on equity has been inconsistent, reflecting variability in profitability.

Cash Flow

Cash flow from operations has been unstable, with periods of negative cash flow. Free cash flow growth has been erratic, but the company has managed to maintain positive free cash flow in recent years. The operating cash flow to net income ratio suggests some challenges in translating income into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	50.68M	129.30M	119.89M	253.03M	265.13M
Gross Profit	28.91M	78.09M	66.76M	100.93M	111.25M
EBITDA	56.52M	71.38M	58.50M	70.55M	59.97M
Net Income	32.48M	40.83M	17.82M	60.32M	83.44M
Balance Sheet
Total Assets	1.67B	1.70B	1.71B	1.74B	1.70B
Cash, Cash Equivalents and Short-Term Investments	36.49M	106.31M	217.28M	387.04M	281.28M
Total Debt	303.06M	297.06M	249.13M	170.42M	154.84M
Total Liabilities	467.29M	442.89M	384.18M	306.35M	299.60M
Stockholders Equity	1.20B	1.25B	1.32B	1.43B	1.40B
Cash Flow
Free Cash Flow	188.62M	-137.32M	42.10M	-89.79M	70.39M
Operating Cash Flow	188.75M	-136.49M	43.15M	-83.27M	70.81M
Investing Cash Flow	-271.59M	53.72M	-134.76M	161.56M	108.14M
Financing Cash Flow	3.87M	-18.90M	41.93M	-38.22M	-108.88M

Meilleure Health International Industry Group Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2327, the sentiment is Negative. The current price of 0.25 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.28, and below the 200-day MA of 0.27, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.18 is Neutral, neither overbought nor oversold. The STOCH value of 46.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2327.

Meilleure Health International Industry Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8162	65 Neutral	HK$527.50M	13.66	58.27%	―	41.04%	84.76%
Sector *	58 Neutral	HK$13.23B	4.28	-2.97%	5.82%	2.91%	-48.85%
2327	48 Neutral	HK$1.04B	32.28	2.65%	1.60%	-60.81%	-21.00%
2322	45 Neutral	HK$1.71B	―	-13.05%	―	-49.15%	-1.89%
0025	42 Neutral	HK$1.20B	―	-4.99%	5.53%	7.83%	-296.70%
0925	40 Underperform	HK$912.98M	―		―	―	―
0474	39 Underperform	HK$147.64M	―	-191.85%	―	-9.49%	5.90%

Meilleure Health International Industry Group Limited Corporate Events

Meilleure Health Announces AGM and Share Repurchase Plan

Meilleure Health International Industry Group Limited has announced its upcoming annual general meeting scheduled for June 27, 2025, in Hong Kong. Key agenda items include the approval of the audited financial statements for 2024, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, a resolution will be considered to authorize the company’s directors to repurchase up to 10% of its shares, enhancing shareholder value and potentially impacting the company’s market position.